We are well-positioned to develop our commercialization infrastructure and market access, leveraging our Controlling Shareholder Kelun Pharmaceutical’s decades-long experience, industry connections and extensive network. Guided by Kelun Pharmaceutical’s leading industry position, strong brand image and profound resources as one of China’s largest and most established pharmaceutical companies, we have developed our own commercialization team and network, with an initial focus on Class III hospitals and leading physicians across China’s extensive local markets. We will also continue to refine our commercialization strategies for each late-stage drug candidate, first prioritizing therapeutic areas with medical needs in China, such as BC, NSCLC and GI cancers, while offering synergistic treatment options enabled by our diverse pipeline to optimize patient outcome.
